Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH.

Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26.

2.

NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.

Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA.

Urology. 2014 Dec;84(6):1427-32. doi: 10.1016/j.urology.2014.07.059.

PMID:
25432832
3.
4.
5.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
6.

Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy.

Moul JW, Chen DY, Trabulsi EJ, Warlick CA, Ruckle HC, Porter JR, Yoshida JS, Adams GW, Kella N, Matsunaga GS, Bans LL, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA; investigators of the ProsVue Field Experience Trial.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):280-5. doi: 10.1038/pcan.2014.25. Epub 2014 Jul 15.

PMID:
25027863
8.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
9.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

10.

Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-7.

11.

Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.

Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.

J Urol. 2001 Dec;166(6):2193-7.

PMID:
11696734
13.

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.

Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2136-41.

PMID:
12771735
14.

Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.

Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, Chou YH, Wu MT.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6632-8.

15.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
16.

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.

Olsson CA, de Vries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, Buttyan RE, Katz AE.

J Urol. 1996 May;155(5):1557-62.

PMID:
8627821
17.

Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.

Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll PR.

Urology. 2002 Apr;59(4):560-5.

PMID:
11927314
18.

Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.

Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Aronson WJ; Search Database Study Group.

J Urol. 2004 Jun;171(6 Pt 1):2215-20.

PMID:
15126788
19.

Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.

Lepor H, Cheli CD, Thiel RP, Taneja SS, Laze J, Chan DW, Sokoll LJ, Mangold L, Partin AW.

BJU Int. 2012 Jun;109(12):1770-5. doi: 10.1111/j.1464-410X.2011.10568.x. Epub 2011 Oct 12.

20.

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.

Freedland SJ, Sutter ME, Dorey F, Aronson WJ.

Urology. 2003 Feb;61(2):365-9.

PMID:
12597949
Items per page

Supplemental Content

Write to the Help Desk